Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioma 3Oligodendroglioma 2Gliosarcoma 2Glioma, Subependymal 2Glioblastoma 2Ependymoma 2Astrocytoma 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Pinealoma 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Neuroectodermal Tumors, Primitive 1Meningioma 1Medulloblastoma 1Healthy, no Evidence of Disease 1Diffuse Intrinsic Pontine Glioma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Endometrioid 1

Interventions

Surgical Procedures, Operative 1Immunohistochemistry 1Ferrosoferric Oxide 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pancreatic Intraductal Neoplasms × Congresses as Topic × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡